ReviewLife (Basel, Switzerland)2026
Depression-Related Mechanistic and Translational Evidence for
Review in Life (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundDepression is a multifactorial psychiatric disorder involving monoaminergic, neurotrophic, inflammatory, oxidative, and stress-response pathways.
objectiveThe aim of this scoping review was to map the available evidence on
methodsA protocol was registered before formal screening, full-text assessment, data charting, and evidence synthesis (INPLASY202670003). Scopus, PubMed/MEDLINE, the Cochrane Library, and ClinicalTrials.gov were searched from inception to 2 July 2026. Eligible studies included human, animal, cell-based, and ex vivo studies reporting depression, depressive-like behavior, antidepressant-like effects, or mechanisms explicitly linked to depression-related pathophysiology. Two reviewers independently screened the identified records and charted the data using a standardized form, with disagreements resolved through consensus or consultation with a third reviewer. The findings were synthesized descriptively and narratively.
resultsA total of 14 studies published between 2008 and 2025 were included, comprising 13 preclinical studies and 1 open-label human study. No eligible cell-based or ex vivo studies were identified. The included studies primarily examined
conclusionsThe available evidence supports the biological plausibility and preclinical antidepressant-like activity of
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.